News

June 11, 2019

Tempus and Leidos Biomedical Research Inc. Launch Effort to Enhance The Cancer Genome Atlas

CHICAGO, June 11, 2019 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale announced today that it was selected by Leidos Biomedical Research Inc. (Leidos Biomed) to abstract and structure follow-up clinical data for The Cancer Genome Atlas ...

June 3, 2019

Tempus Announces (TIME) Trial Service, a New Integrated Molecular Evaluation that Leverages Artificial Intelligence to Rapidly Match Cancer Patients to Clinical Trials

CHICAGO, June 03, 2019 (GLOBE NEWSWIRE) — Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data at scale, announced today a new service, Tempus Integrated Molecular Evaluation (TIME) Trial, which aims to increase clinical trial enrollment and participation for cancer patients...

May 30, 2019

Tempus Announces $200 Million in Series F Financing

CHICAGO, May 30, 2019 (GLOBE NEWSWIRE) — Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an additional $200M financing at a value of $3.1 billion dollars. The investors include Baillie Gifford, Franklin Templeton, NEA, Novo Holdings, Revolution Growth...

May 21, 2019

Eric Lefkofsky discusses reshaping the existing health care model at Milken Global Conference.

Eric Lefkofsky and Margaret Anderson discuss the road ahead for the health care industry. Video linked here.    

April 29, 2019

Tempus and Feist-Weiller Cancer Center at LSU Health Shreveport Announce Brain Cancer Research Collaboration

Chicago, April 29 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced a new research collaboration with the Feist-Weiller Cancer Center at LSU aimed at improving outcomes for patients battling brain cancer.   As part of this research study, Tempus...

April 12, 2019

Tempus and Huntsman Cancer Institute at the University of Utah Partnering on Pancreatic Cancer Research Initiative

Chicago, April 12 – Tempus, a leading technology company advancing precision medicine through the collection and analysis of molecular and clinical data announced a new collaboration with the Huntsman Cancer Institute at the University of Utah (HCI) aimed at improving outcomes for patients diagnosed with pancreatic cancer. While personalized treatment app...

January 10, 2019

ASCO and Tempus Announce Collaboration to Help Research Sites Identify Potential Participants for the Targeted Agent and Profiling Utilization (TAPUR™) Study

ALEXANDRIA, Va. and CHICAGO, Jan. 10, 2019 (GLOBE NEWSWIRE) — The American Society of Clinical Oncology, Inc. (ASCO) and Tempus announced today an agreement to support research sites participating in ASCO’s Targeted Agent and Profiling Utilization (TAPUR™) Study. The TAPUR Study is a prospective, non-randomized clinical trial that aim...

December 19, 2018

Tempus Announces Next Phase of Biological Modeling Efforts

December 19 – Tempus, a technology company advancing precision medicine through the collection and analysis of molecular and clinical data, announced today an expansion of its biological modeling work to include profiling therapeutic responses across hundreds of unique patient derived organoid models. Tempus has been working with researchers...

December 5, 2018

Tempus Founder and CEO Eric Lefkofsky speaks with Bloomberg Businessweek’s Max Chafkin at Bloomberg’s The Year Ahead summit in New York.

Eric Lefkofsky and Max Chafkin discuss data-driven medicine. Video linked here.  

December 3, 2018

Tempus Ramps Up AI-Driven Precision Oncology, Eyes Other Markets

Dec 03, 2018 | Neil Versel  CHICAGO (GenomeWeb) – Having raised some $320 million in funding since its launch in 2015, cancer informatics and precision medicine company Tempus continues to ramp up its clinical and molecular data collection and curation to support precision oncology, and is beginning to turn its attention to other disease areas. In Septembe...

Show More